Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.43 |
| ▸ | RELA | Q04206 | 7/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8645381 | 0.80 | NFKB1 (0.50) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL8397801 | 0.80 | NFKB1 (0.50) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL27022473 | 0.78 | GAA (0.50) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL27419986 | 0.77 | GAA (0.46) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL27419914 | 0.75 | GAA (0.44) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL12367685 | 0.74 | GAA (0.55) | GAA | |
| SCHEMBL2176628 | 0.74 | GAA (0.55) | GAA | |
| SCHEMBL23513495 | 0.72 | GAA (0.59) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4760856 | 0.72 | GAA (0.59) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL14277693 | 0.72 | GAA (0.59) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | GAA 2016/4885NFKB1 1232/4885NFKB2 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.